---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-008113"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:48:28.734648+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine reports FY2023 net loss of $198.1M; eyes IND/CTA for CGD in 1H 2024

## Summary
- Net loss widened to $198.1M in FY2023 ($121.8M in FY2022); R&D expenses $147.9M up from $86.7M.
- Cash, equivalents, investments, restricted cash $135.2M at Dec 31, 2023, vs $307.4M year earlier.
- Closed upsized public offering in Feb 2024, gross proceeds ~$161.0M at $6.25 per share.
- Expects to file IND/CTA for PM359 (CGD) in 1H 2024; initial clinical data anticipated in 2025.
- Received Orphan Drug Designation for PM359; $15M CF Foundation funding for CF Prime Editors.

## SEC filing metadata
- accession: 0001628280-24-008113
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/0001628280-24-008113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/prme-20240301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-008113
- JSON: https://secwatch.observer/filing/0001628280-24-008113.json
- Plain text: https://secwatch.observer/filing/0001628280-24-008113.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported the full year ended December 31, 2023 results: net income $198.1 million.
  - Period: the full year ended December 31, 2023
  - Net income: $198.1 million
  - Result: reported results
  source text: Net loss was $198.1 million for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828024008113/0001628280-24-008113-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.